Wall Street Wire News Releases

StreetWatch: As Washington Puts a 100 Percent Tariff on Foreign Drones, the Magnet Inside Them Comes Into Focus

Tue, 18 Aug 2026 08:30:00 -0400

Washington just put a 100 percent tariff on the most sensitive foreign drones and certain parts. That is a magnet problem. Every rotor motor, gimbal, and actuator in a modern unmanned aircraft runs on rare earth permanent magnets.The tariff is telling every domestic drone builder to find non-China magnets, and to find them fast. Stack that on the January 1, 2027 Pentagon rule that bars Chinese-origin magnets in covered defense systems, and the shopping list is the same chemistry.Most of the U.S....

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Thu, 06 Aug 2026 09:40:00 -0400

Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales. Palatin Technologies (NASDAQ: PTN) previously advanced the first...

StreetWatch: As Federal Funding Floods the Drone Market, Quantum Cyber Is Assembling a Next Generation Platform

Mon, 03 Aug 2026 10:51:00 -0400

Washington's drone strategy is accelerating on two fronts: pouring unprecedented capital into domestic production while aggressively targeting the supply chains behind Iranian UAVs. Quantum Cyber N.V. (NASDAQ: QUCY) appears positioned squarely within that emerging policy corridor. Through its U.S. subsidiary, the company has acquired an equipped 50,000-square-foot manufacturing facility in Connecticut, established a federal procurement vehicle, and outlined plans to produce up to 100,000 drones...

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Tue, 14 Jul 2026 10:40:00 -0400

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights:Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal,...